Fibrocystic Breast Changes
ICD-10 N60.1; N60.2; N60.3 · ICD-11 GB20.0

Fibrocystic Breast Changes When Dietary and Lifestyle Measures Have Not Controlled Cyclic Breast Pain

When initial non-pharmacological management fails to achieve the expected reduction in cyclic breast pain, tenderness, and swelling, a structured pharmacological next step becomes the appropriate course. This protocol addresses that specific clinical threshold.

Prior management: Non-pharmacological measures

Reassurance, education and counseling; guidance on a properly fitted supportive bra; dietary changes including a fat-restricted diet and restriction of methylxanthines (caffeine) and nicotine — did not achieve the expected improvement or reduction in cyclic breast pain, tenderness, and swelling.

This protocol calls for a specific plant-derived oil as the first-line pharmacological agent, with an established alternative plant-based option for those who require it. The full selection criteria, sequencing, and clinical management algorithm are available in the complete protocol.

Good response in mastalgia (breast pain) and breast nodularity

References

Owing to its rich content of omega-6 essential fatty acid, GLA, evening primrose oil has been an important treatment for FBD.

Early studies on EPO found a good response rate in patients with mastalgia and nodularity and went on to recommend it as the first line therapy.

Flaxseed oil, a source of alpha-linolenic acid, has also been shown to reduce breast pain in randomized placebo-controlled trials.

Though not many studies have been carried out to establish its efficacy, some authorities have recommended it as the first-line therapy.

View source ↗